Menopause transition and cardiovascular disease risk

Uddenberg, Erin R.; Safwan, Nancy; Saadedine, Mariam; Hurtado, Maria D.; Faubion, Stephanie S.; Shufelt, Chrisandra L.

doi:10.1016/j.maturitas.2024.107974

Cited by 8 publications

(2 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This association is linked to the sudden decline in estrogen levels caused by surgery, which can lead to endothelial dysfunction, dyslipidemia [1,[26][27][28][29], and increased risk of cardiovascular events [30][31][32][33][34]. Research suggests a 1.5-fold to 9.7-fold increased risk of MetS in women who undergo surgical menopause compared to natural menopause [1,[35][36][37][38][39].…”

Section: Surgical Menopause and Increased Mets Riskmentioning

confidence: 99%

Metabolic Syndrome and Survival Outcomes in Endometrial Cancer

Marin,

Filipescu,

Vladareanu

et al. 2024

Cureus

View full text Add to dashboard Cite

Menopause, through attributable estrogen level decline and the corresponding increase in circulating androgens, significantly elevates a woman's risk for cardiometabolic diseases, including metabolic syndrome (MetS), type 2 diabetes, and cardiovascular disease. Metabolic syndrome itself is a cluster of interconnected risk factors, and among them, central obesity is a well-established factor for the development of endometrial cancer (EC), the most common gynecologic malignancy. This research investigates the impact of metabolic syndrome on survival rates among patients with endometrial cancer. The goal is to assess whether having metabolic syndrome or its individual components influences disease-free survival (DFS), overall survival (OS), cancer-specific survival, and recurrence rates. Understanding this link is crucial for determining risk levels and could help tailor treatment approaches for better long-term outcomes in endometrial cancer care.

show abstract

Section: Surgical Menopause and Increased Mets Riskmentioning

confidence: 99%

Metabolic Syndrome and Survival Outcomes in Endometrial Cancer

Marin,

Filipescu,

Vladareanu

et al. 2024

Cureus

View full text Add to dashboard Cite

show abstract

“…The menopausal transition, also termed perimenopause, is defined as the phase in middle-age during which a woman transitions from a reproductive to a non-reproductive period. Perimenopause is characterized by sudden increases and decreases in estrogen levels linked to the aging of ovaries, and the transition to a non-reproductive life; this imbalance in the hormone milieu produces intense symptoms such as hot flushes, insomnia, irritability, and low libido ( 6 , 7 ). Fluctuations in estrogen levels during perimenopause have also been linked to symptoms of depression, anxiety, and mild cognitive complaints, which are particularly relevant in a subset of middle-aged women with high sensitivity to extreme changes in estrogen levels, as they might suffer from psychiatric disorders that require treatment ( 4 , 8 , 9 ).…”

Section: Introductionmentioning

confidence: 99%

The intersection between menopause and depression: overview of research using animal models

Herrera-Pérez,

Hernández-Hernández,

Flores-Ramos

et al. 2024

Front. Psychiatry

View full text Add to dashboard Cite

Menopausal women may experience symptoms of depression, sometimes even progressing clinical depression requiring treatment to improve quality of life. While varying levels of estrogen in perimenopause may contribute to an increased biological vulnerability to mood disturbances, the effectiveness of estrogen replacement therapy (ERT) in the relief of depressive symptoms remains controversial. Menopausal depression has a complex, multifactorial etiology, that has limited the identification of optimal treatment strategies for the management of this psychiatric complaint. Nevertheless, clinical evidence increasingly supports the notion that estrogen exerts neuroprotective effects on brain structures related to mood regulation. Indeed, research using preclinical animal models continues to improve our understanding of menopause and the effectiveness of ERT and other substances at treating depression-like behaviors. However, questions regarding the efficacy of ERT in perimenopause have been raised. These questions may be answered by further investigation using specific animal models of reduced ovarian function. This review compares and discusses the advantages and pitfalls of different models emulating the menopausal stages and their relationship with the onset of depressive-like signs, as well as the efficacy and mechanisms of conventional and novel ERTs in treating depressive-like behavior. Ovariectomized young rats, middle-to-old aged intact rats, and females treated with reprotoxics have all been used as models of menopause, with stages ranging from surgical menopause to perimenopause. Additionally, this manuscript discusses the impact of organistic and therapeutic variables that may improve or reduce the antidepressant response of females to ERT. Findings from these models have revealed the complexity of the dynamic changes occurring in brain function during menopausal transition, reinforcing the idea that the best approach is timely intervention considering the opportunity window, in addition to the careful selection of treatment according to the presence or absence of reproductive tissue. Additionally, data from animal models has yielded evidence to support new promising estrogens that could be considered as ERTs with antidepressant properties and actions in endocrine situations in which traditional ERTs are not effective.

show abstract